Product/Composition:- | Niclocide tablet |
---|---|
Strength:- | 500 mg |
Form:- | Tablets |
Reference Brands:- | Niclocide(US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Niclosamide tablets inhibit mitochondrial respiration in tapeworms, disrupting their energy production and causing paralysis and death. It effectively treats intestinal tapeworm infections, providing rapid symptom relief, parasite elimination, and preventing transmission. Benefits include safe, effective eradication of parasites and improved gastrointestinal health.
Niclosamide tablets, marketed as Niclocide and generics, are approved in the US and EU mainly for intestinal tapeworm infections. Regulatory approval requires comprehensive dossiers, including clinical efficacy, safety profiles, manufacturing quality, and pharmacovigilance plans. In the US, the FDA reviews clinical trial and manufacturing data, while the EMA ensures regional safety and quality compliance. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper adherence supports timely approval, safe use, and global availability, enabling effective treatment of cestode infections worldwide and supporting gastrointestinal health in regions with parasitic disease burdens.